do Nascimento Santos João Vitor, de Moraes Pablo Winícius Sousa, Pereira Matheus Nobrega, Costa Leite Juan Vitor, Magalhães Gabriela de Alencar Pinto, Capehart Kim, de Andrade Ana Karina Maciel, Wanderley E Lima Renally Bezerra
Department of Dentistry, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
Department of Restorative Dentistry, Federal University of Paraiba, Campus I Lot. Cidade Universitária, João Pessoa, Paraíba, Brazil.
Clin Oral Investig. 2025 Sep 17;29(10):464. doi: 10.1007/s00784-025-06516-w.
To systematically map and synthesize the current scientific evidence on the active ingredients and effectiveness of bioactive glass-containing products for the treatment of dentin hypersensitivity, and to identify knowledge gaps.
This scoping review followed PRISMA-ScR guidelines and was registered on the Open Science Framework platform. Searches were conducted in PubMed/MEDLINE, Embase, Scopus, and Web of Science up to March 2025. Studies of any evidence level investigating bioactive glasses, bioactive glass-ceramics, or related products for dentin hypersensitivity treatment, evaluating parameters like dentinal tubule occlusion, dental remineralization, or pain relief, were included. Descriptive analysis was applied to all included studies.
A total of 72 studies were reviewed, primarily in vitro (n = 46), with randomized clinical trials (n = 17) and reviews (n = 9) also represented. Calcium sodium phosphosilicate was the most analyzed bioactive glass (n = 33), often compared with arginine, nano-hydroxyapatite, potassium nitrate, and strontium acetate formulations. Products were commonly presented as toothpaste (n = 39), powder (n = 14), and gel (n = 6). In vitro studies frequently reported benefits in dentinal tubule occlusion, predominantly assessed by scanning electron microscopy. Clinical studies demonstrated reductions in dentin hypersensitivity-related pain, commonly assessed using air jet or cold-water stimuli combined with Visual Analog Scale (VAS) scores or the Schiff Cold Air Sensitivity Scale (SCSS), with follow-up periods ranging from 1 to 11 weeks.
Toothpaste containing calcium sodium phosphosilicate was the most extensively studied bioactive glass-based product for dentin hypersensitivity treatment, with in vitro evidence supporting its effectiveness. Additional clinical research is needed to confirm these findings.
Bioactive glass products show promise in the treatment of dentin hypersensitivity. Given the variability in composition, evidence-based selection is key to ensuring effective treatment and improving patient outcomes.
系统梳理和综合当前关于含生物活性玻璃产品治疗牙本质过敏症的活性成分及有效性的科学证据，并找出知识空白。
本范围综述遵循PRISMA-ScR指南，并在开放科学框架平台上进行了注册。截至2025年3月，在PubMed/MEDLINE、Embase、Scopus和Web of Science数据库中进行了检索。纳入了任何证据水平的研究，这些研究调查用于牙本质过敏症治疗的生物活性玻璃、生物活性玻璃陶瓷或相关产品，评估诸如牙本质小管堵塞、牙齿再矿化或疼痛缓解等参数。对所有纳入研究进行描述性分析。
共审查了72项研究，主要是体外研究（n = 46），也包括随机临床试验（n = 17）和综述（n = 9）。磷酸硅钙钠是分析最多的生物活性玻璃（n = 33），常与精氨酸、纳米羟基磷灰石、硝酸钾和醋酸锶配方进行比较。产品常见形式为牙膏（n = 39）、粉末（n = 14）和凝胶（n = 6）。体外研究经常报告在牙本质小管堵塞方面有好处，主要通过扫描电子显微镜评估。临床研究表明牙本质过敏症相关疼痛有所减轻，通常使用空气喷射或冷水刺激结合视觉模拟量表（VAS）评分或希夫冷空气敏感性量表（SCSS）进行评估，随访期为1至11周。
含磷酸硅钙钠的牙膏是用于牙本质过敏症治疗的研究最广泛的基于生物活性玻璃的产品，体外证据支持其有效性。需要更多临床研究来证实这些发现。
生物活性玻璃产品在牙本质过敏症治疗中显示出前景。鉴于成分的变异性，基于证据的选择是确保有效治疗和改善患者预后的关键。
